Browse > Article

MRI Findings of Triple Negative Breast Cancer: A Comparison with Non-Triple Negative Breast Cancer  

Choi, Jae-Jeong (Department of Radiology, College of Medicine, The Catholic University of Korea)
Kim, Sung-Hun (Department of Radiology, College of Medicine, The Catholic University of Korea)
Cha, Eun-Suk (Department of Radiology, College of Medicine, The Catholic University of Korea)
Kang, Bong-Joo (Department of Radiology, College of Medicine, The Catholic University of Korea)
Lee, Ji-Hye (Department of Radiology, College of Medicine, The Catholic University of Korea)
Lee, So-Yeon (Department of Radiology, College of Medicine, The Catholic University of Korea)
Jeong, Seung-Hee (Clinical Research Coordinating Center, College of Medicine, The Catholic Medical Center)
Yim, Hyeon-Woo (Clinical Research Coordinating Center, College of Medicine, The Catholic Medical Center)
Song, Byung-Joo (Department of Surgery, College of Medicine, The Catholic University of Korea)
Publication Information
Investigative Magnetic Resonance Imaging / v.14, no.2, 2010 , pp. 95-102 More about this Journal
Abstract
Purpose : To evaluate the magnetic resonance imaging (MRI) and clinicopathological features of triple negative breast cancer, and compare them with those of non-triple negative breast cancer. Materials and Methods : This study included 231 pathologically confirmed breast cancers from January 2007 to May 2008. We retrospectively reviewed the MRI findings according to the Breast Imaging Reporting and Data System (BI-RADS) lexicon: mass or non-mass type, mass shape, mass margin, non-mass distribution, and enhancement pattern. Histologic type, histologic grade, and the results for epidermal growth factor receptor, p53, and Ki 67 were reviewed. Results : Of 231 patients, 43(18.6%) were triple negative breast cancer. Forty triple negative breast cancers (93.0%) were mass-type lesion on MRI. A round or oval or lobular shape (p=0.006) and rim enhancement (p=0.004) were significantly more in triple negative breast cancer than non- triple negative breast cancer. In contrast, irregular shape (p=0.006) and spiculated margins (p=0.032) were significantly more in non-triple negative breast cancer. Old age (p=0.019), high histologic grade (p<0.0001), EGFR positivity (p<0.0001), p53 overexpression (p=0.038), and Ki 67 expression (<0.0001) were significantly associated with the triple negative breast cancer. Conclusion : MRI finding may be helpful for differentiation between triple negative and non-triple negative breast cancer.
Keywords
Breast cancer; Estrogen receptor; Progesterone receptor; HER2; Magnetic resonance imaging (MRI);
Citations & Related Records
연도 인용수 순위
  • Reference
1 Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009;20:1071-1082   DOI   ScienceOn
2 Yang WT, Dryden M, Broglio K, et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 2008;111:405-410   DOI   ScienceOn
3 Corkery B, Crown J, Clynes M, O Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009;20:862-867   DOI   ScienceOn
4 Rosen EL, Smith-Foley SA, DeMartini WB, Eby PR, Peacock SLehman CD. BI-RADS MRI enhancement characteristics of ductal carcinoma in situ. Breast J 2007;13:545-550   DOI   ScienceOn
5 Facius M, Renz DM, Neubauer H, et al. Characteristics of ductal carcinoma in situ in magnetic resonance imaging. Clin Imaging 2007;31:394-400   DOI   ScienceOn
6 Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006;49: 10-21   DOI   ScienceOn
7 Sasaki Y, Tsuda H. Clinicopathological characteristics of triple-negative breast cancers. Breast Cancer 2009;16:254-259   DOI   ScienceOn
8 Rolland P, Spendlove I, Madjd Z, et al. The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. Int J Cancer 2007;120:1311-1317
9 Leibl S, Moinfar F. Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol 2005;58:700-704   DOI   ScienceOn
10 Reis-Filho JS, Milanezi F, Carvalho S, et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 2005;7: R1028-1035   DOI
11 Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat 2009;117:273-280   DOI   ScienceOn
12 Chae BJ, Bae JS, Lee A, et al. p53 as a specific prognostic factor in triple-negative breast cancer. Jpn J Clin Oncol 2009;39:217-224   DOI   ScienceOn
13 Chen JH, Agrawal G, Feig B, et al. Triple-negative breast cancer: MRI features in 29 patients. Ann Oncol 2007;18:2042- 2043   DOI   ScienceOn
14 Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology 2009;250:638-647   DOI   ScienceOn
15 Iwase H, Kurebayashi J, Tsuda H, et al. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer 17:118-124
16 Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-4434   DOI   ScienceOn
17 Viale G, Regan MM, Mastropasqua MG, et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008;100:207-212   DOI   ScienceOn
18 Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008;52:108-118
19 Ding SL, Sheu LF, Yu JC, et al. Expression of estrogen receptor-alpha and Ki67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma. J Biomed Sci 2004;11:911-919
20 Nogi H, Kobayashi T, Suzuki M, et al. EGFR as paradoxical predictor of chemosensitivity and outcome among triplenegative breast cancer. Oncol Rep 2009;21:413-417
21 Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H. Clinical significance of basal-like subtype in triplenegative breast cancer. Breast Cancer 2009;16:260-267   DOI   ScienceOn
22 Kuroda N, Fujishima N, Inoue K, et al. Basal-like carcinoma of the breast: further evidence of the possibility that most metaplastic carcinomas may be actually basal-like carcinomas. Med Mol Morphol 2008;41:117-120   DOI   ScienceOn
23 Viale G, Rotmensz N, Maisonneuve P, et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009;116:317-328   DOI   ScienceOn
24 Biswas DK, Iglehart JD. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. J Cell Physiol 2006;209:645-652   DOI   ScienceOn